Journal of advanced research · 2026
Luteolin as a novel therapeutic for diabetic kidney disease: Targeting the ADAM10-TREM2 pathway.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Deng Lingchen, Wang Yong, Shi Chunru, Wu Jie, Yao Jin, Shen Wanjun, Zhang Ziyue, Liu Ran, Wang Xu, Zhu Hanyu, Zhang Li, Cai Guangyan, Zhou Jianhui, Hong Quan, Chen Xiangmei
Аннотация
BACKGROUND: Diabetic kidney disease (DKD) is a common condition with few treatment options, and inflammation plays a pivotal role in its progression. Luteolin, a natural compound found in traditional Chinese herbs, is known for its anti-inflammatory properties, making it a potential treatment for DKD. But its effect and mechanisms in DKD remain incompletely elucidated.
METHODS: Renoprotective effects of luteolin in db/db mice were assessed with BUN, Scr, uACR, and PAS staining. Flow cytometry and extraction of total membrane proteins were conducted to examine the abundance of full-length TREM2 on the membrane of macrophages. Co-culture of differentially treated macrophages and HK2 cells evaluated luteolin's impact on efferocytosis. The molecular target of luteolin was elucidated through virtual molecular analysis, SPR, and ADAM10 activity assays.
RESULTS: Luteolin reduced uACR, BUN, and SCr levels. Histologic analyses showed decreases in mesangial matrix, glomerular volume, GBM thickness, and foot process effacement. Tubular injury scores and KIM1 expression were lowered, while megalin and cubilin expression increased. Renal macrophage infiltration, iNOS+ cells, and IL-1β, IL-18, TNF-α, and MCP-1 levels were reduced. Luteolin elevated TREM2+ macrophages with decreased sTREM2 in vivo and in vitro. Immunofluorescence confirmed increased TREM2+ macrophages and enhanced full-length TREM2 on cell membrane. Luteolin exhibited dose-dependent binding to ADAM10 and inhibited its activity without affecting ADAM10 expression. In co-culture system, luteolin increased p-DAP12, p-SYK, and PHrodo+ cell counts. Apoptotic cells in kidney tissue decreased, while Rab5a and Rab7a expression were upregulated.
CONCLUSIONS: Luteolin attenuates immunoinflammation and pathological injury in db/db mice by enhancing the efferocytosis of apoptotic renal tubular cells by TREM2+ macrophages. The potential mechanism of luteolin involves binding to ADAM10 and inhibiting its activity, which attenuates aberrant shedding of full-length TREM2 from macrophages and potentiates downstream TREM2 signaling. Collectively, luteolin provides a promising option for ameliorating immune inflammation in DKD, demonstrating strong translational potential.
METHODS: Renoprotective effects of luteolin in db/db mice were assessed with BUN, Scr, uACR, and PAS staining. Flow cytometry and extraction of total membrane proteins were conducted to examine the abundance of full-length TREM2 on the membrane of macrophages. Co-culture of differentially treated macrophages and HK2 cells evaluated luteolin's impact on efferocytosis. The molecular target of luteolin was elucidated through virtual molecular analysis, SPR, and ADAM10 activity assays.
RESULTS: Luteolin reduced uACR, BUN, and SCr levels. Histologic analyses showed decreases in mesangial matrix, glomerular volume, GBM thickness, and foot process effacement. Tubular injury scores and KIM1 expression were lowered, while megalin and cubilin expression increased. Renal macrophage infiltration, iNOS+ cells, and IL-1β, IL-18, TNF-α, and MCP-1 levels were reduced. Luteolin elevated TREM2+ macrophages with decreased sTREM2 in vivo and in vitro. Immunofluorescence confirmed increased TREM2+ macrophages and enhanced full-length TREM2 on cell membrane. Luteolin exhibited dose-dependent binding to ADAM10 and inhibited its activity without affecting ADAM10 expression. In co-culture system, luteolin increased p-DAP12, p-SYK, and PHrodo+ cell counts. Apoptotic cells in kidney tissue decreased, while Rab5a and Rab7a expression were upregulated.
CONCLUSIONS: Luteolin attenuates immunoinflammation and pathological injury in db/db mice by enhancing the efferocytosis of apoptotic renal tubular cells by TREM2+ macrophages. The potential mechanism of luteolin involves binding to ADAM10 and inhibiting its activity, which attenuates aberrant shedding of full-length TREM2 from macrophages and potentiates downstream TREM2 signaling. Collectively, luteolin provides a promising option for ameliorating immune inflammation in DKD, demonstrating strong translational potential.